Preventing Graft-Versus-Host Disease
In Vivo Prevention of Murine GVHD
This work explores how special immune cells called ILC2s might help prevent or treat graft-versus-host disease after a bone marrow transplant.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-11124684 on NIH RePORTER |
What this research studies
After a bone marrow transplant, patients often face a serious complication called graft-versus-host disease (GVHD), where the new immune cells attack the patient's body. Our team found that important immune cells, called ILC2s, are severely reduced by treatments like radiation or chemotherapy. We are looking into whether adding donor ILC2s or boosting their activity with a protein called IL-33 could protect against GVHD. This approach aims to reduce inflammation and help repair damaged tissues, especially in the gut. We are also studying how these cells interact with other factors to promote healing.
Who could benefit from this research
Good fit: This research is relevant for patients who have undergone or are preparing for a bone marrow transplant and are at risk for graft-versus-host disease.
Not a fit: Patients not undergoing bone marrow transplantation or those without risk factors for graft-versus-host disease would not directly benefit from this specific approach.
Why it matters
Potential benefit: If successful, this work could lead to new ways to prevent or lessen the severity of graft-versus-host disease, improving outcomes for patients undergoing bone marrow transplants.
How similar studies have performed: This work presents novel findings on the role of ILC2s and IL-33 in preventing GVHD, building upon existing knowledge of immune cell therapies.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Blazar, Bruce R — University of Minnesota
- Study coordinator: Blazar, Bruce R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.